Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.

Expert opinion on drug metabolism & toxicology - 1 Sept 2013

Perera Vidya, Gross Annette S, Polasek Thomas M, Qin Yan, Rao Gauri, Forrest Alan, Xu Junzhe, McLachlan Andrew J

Abstract excerpt

INTRODUCTION: Schizophrenia, a mental disorder, is a debilitating condition which typically strikes young people in their early 20's. Antipsychotic medications are widely prescribed for the treatment of schizophrenia however a balancing act is necessary to provide the correct dose to each patient. It is suggested that a large number of patients discontinue antipsychotic pharmacotherapy because the treatments...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Dose-Response Relationship, Drug

Share to Genotype

Share to Olanzapine

Share to Pharmacogenetics

Share to Schizophrenia

Source

Identifiers

PMID: 23641727
DOI: 10.1517/17425255.2013.795540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.PMID 23641727Read ↗

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.Semantic proximity Read ↗

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Semantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.Semantic proximity Read ↗

Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic TreatmentsSemantic proximity Read ↗

The Role of Pharmacogenetic Testing in Optimizing Antipsychotic TherapySemantic proximity Read ↗

Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy.Semantic proximity Read ↗

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Semantic proximity Read ↗

Pharmacogenetics of antipsychotics: useful for the clinician?Semantic proximity Read ↗

Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications.Semantic proximity Read ↗

Pharmacogenetics of Olanzapine MetabolismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.